Table 3. Project MIX, multivariate results for outcome behaviors, by group at assessment wave, 2004–2008.

Group	Primary Outcomes, AOR (CI)						Secondary Outcomes, AOR (CI)
	UA	DUA	Alcohol-UA	Drug-UA	Alcohol-DUA	Drug-DUA	URA	UIA	Substance Use during Sexa
2-Group analysis for 3-, 6-, 12-mo follow-up waves ( n  = 1,206)
Attention-control (referent)
Intervention	0.95 (0.72–1.26)	1.06 (0.82–1.38)	1.15 (0.88–1.50)	1.07 (0.81–1.42)	1.25 (0.93–1.67)	1.04 (0.77–1.40)	0.85 (0.64–1.13)	1.15 (0.87–1.52)	0.96 (0.70–1.30)
Follow-up (baseline, referent)
3 mo	0.34 (0.26–0.43)	0.41 (0.31–0.54)	0.37 (0.28–0.49)	0.36 (0.27–0.47)	0.40 (0.29–0.57)	0.42 (0.30–0.58)	0.46 (0.35–0.61)	0.48 (0.36–0.63)	0.27 (0.21–0.36)
6 mo	0.29 (0.23–0.38)	0.34 (0.25–0.45)	0.37 (0.28–0.49)	0.32 (0.24–0.42)	0.32 (0.23–0.45)	0.28 (0.19–0.40)	0.40 (0.30–0.53)	0.50 (0.37–0.66)	0.24 (0.18–0.31)
12 mo	0.24 (0.18–0.31)	0.37 (0.28–0.49)	0.27 (0.20–0.36)	0.25 (0.18–0.33)	0.34 (0.24–0.48)	0.33 (0.24–0.47)	0.33 (0.25–0.43)	0.40 (0.31–0.54)	0.19 (0.14–0.25)
Intervention group comparisons
Baseline—Interv (versus Attn)	0.95 (0.71–1.27)	1.06 (0.81–1.39)	1.15 (0.88–1.51)	1.07 (0.80–1.43)	1.25 (0.92–1.69)	1.04 (0.76–1.41)	0.85 (0.63–1.14)	1.15 (0.86–1.53)	0.96 (0.69–1.32)
3 mo—Interv (versus Attn)	0.93 (0.70–1.22)	0.89 (0.64–1.23)	0.99 (0.72–1.37)	1.06 (0.77–1.46)	0.88 (0.58–1.32)	0.92 (0.62–1.37)	0.86 (0.63–1.19)	1.11 (0.81–1.53)	1.13 (0.85–1.49)
6 mo—Interv (versus Attn)	1.01 (0.76–1.33)	0.89 (0.64–1.25)	0.94 (0.68–1.30)	1.26 (0.91–1.75)	0.87 (0.56–1.35)	1.14 (0.74–1.76)	0.94 (0.67–1.30)	1.03 (0.75–1.42)	1.12 (0.85–1.49)
12-mo—Interv (versus Attn)	1.14 (0.86–1.51)	0.92 (0.66–1.28)	1.06 (0.75–1.49)	1.21 (0.86–1.70)	0.86 (0.56–1.32)	0.98 (0.64–1.48)	1.27 (0.91–1.77)	1.05 (0.75–1.47)	1.10 (0.83–1.45)
3-Group analysis for 3-mo follow-up waves ( n  = 1,686)
Standard (referent)
Intervention	0.93 (0.71–1.23)	0.87 (0.67–1.13)	1.00 (0.77–1.31)	1.13 (0.86–1.48)	0.97 (0.73–1.30)	1.00 (0.74–1.36)	0.84 (0.64–1.12)	1.17 (0.89–1.54)	1.04 (0.77–1.40)
Attention-control	0.97 (0.74–1.28)	0.84 (0.64–1.09)	0.88 (0.68–1.15)	1.05 (0.80–1.38)	0.80 (0.59–1.07)	0.97 (0.71–1.31)	0.98 (0.74–1.30)	1.03 (0.78–1.35)	1.09 (0.81–1.48)
Follow-up (baseline, referent)
3-mo	0.34 (0.26–0.45)	0.39 (0.29–0.53)	0.35 (0.26–0.47)	0.39 (0.29–0.53)	0.35 (0.25–0.5)	0.39 (0.27–0.57)	0.52 (0.37–0.72)	0.50 (0.36–0.69)	0.37 (0.27–0.49)
Intervention group comparisons
Baseline—Interv (versus Attn)	0.96 (0.73–1.26)	1.05 (0.81–1.35)	1.14 (0.88–1.47)	1.07 (0.82–1.39)	1.22 (0.91–1.62)	1.04 (0.77–1.39)	0.86 (0.65–1.13)	1.14 (0.88–1.49)	0.95 (0.70–1.28)
Baseline—Interv (versus Stand)	0.93 (0.70–1.24)	0.87 (0.67–1.14)	1.00 (0.77–1.32)	1.13 (0.85–1.50)	0.97 (0.72–1.31)	1.00 (0.73–1.37)	0.84 (0.63–1.13)	1.17 (0.88–1.56)	1.04 (0.76–1.42)
Baseline—Attn (versus Stand)	0.97 (0.73–1.30)	0.84 (0.64–1.09)	0.88 (0.67–1.16)	1.05 (0.79–1.39)	0.80 (0.59–1.08)	0.97 (0.70–1.32)	0.98 (0.74–1.32)	1.03 (0.77–1.37)	1.09 (0.80–1.50)
3 mo—Interv (versus Attn)	0.95 (0.73–1.23)	0.88 (0.65–1.20)	1.00 (0.74–1.36)	1.06 (0.79–1.42)	0.86 (0.58–1.27)	0.93 (0.64–1.36)	0.88 (0.65–1.19)	1.15 (0.85–1.54)	1.12 (0.87–1.45)
3 mo—Interv (versus Stand)	0.95 (0.72–1.25)	0.78 (0.57–1.08)	0.98 (0.71–1.36)	1.09 (0.79–1.51)	0.79 (0.53–1.19)	0.96 (0.63–1.45)	0.80 (0.58–1.11)	1.18 (0.86–1.63)	0.98 (0.74–1.29)
3 mo—Attn (versus Stand)	0.99 (0.75–1.31)	0.89 (0.65–1.22)	0.98 (0.71–1.36)	1.03 (0.74–1.43)	0.93 (0.62–1.38)	1.03 (0.69–1.55)	0.91 (0.66–1.26)	1.03 (0.75–1.42)	0.87 (0.67–1.15)

Controlled for all variables listed plus city, age, race/ethnicity, education level, sexual orientation identification, and HIV serostatus.

AOR, adjusted odds ratio; Attn, attention-control group; Interv, intervention group; Stand, standard of care group; UIA, unprotected insertive anal sex; URA, unprotected receptive anal sex.

^aSubstance use soon before or during most recent anal sex encounter.